Paz J. Vellanki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paz J. Vellanki has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Alexander William Wyatt
Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
1 shared publication - Alice P. Chen
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, USA
1 shared publication - Aliyah Pabani
The Sidney Kimmel Comprehensive Cancer Center 1 , Johns Hopkins University School of Medicine, Baltimore, Maryland
1 shared publication Allison Winter
Department of Internal Medicine, Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Health, USA
1 shared publication- Archana Balan
The Sidney Kimmel Comprehensive Cancer Center 1 , Johns Hopkins University School of Medicine, Baltimore, Maryland
1 shared publication Bayard L. Powell
Department of Internal Medicine, Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Health, USA
1 shared publication
Latest Publications
- Open Access
- 24 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF19
Landmark ctDNA Molecular Response Represents an Early Predictor of Immunotherapy Outcomes in Lung Cancer: A Clinical Validity Study
Purpose: Circulating tumor DNA (ctDNA) analyses are informative as an early indicator of immunotherapy response in advanced non–small cell lung cancer (NSCLC); however, the clinical value of ctDNA molecular response (mR) requires further validation. Experimental Design: As part of a prospective clinical protocol (NCT05995821), we conducted targeted error-correction sequencing of ctDNA (n = 328) and matched white blood cell (WBC) DNA (n = 109) from 109 patients with metastatic NSCLC who received anti–PD-(L)1 either as monotherapy or in combination. Following cellular origin resolution of 2,818 variants, landmark mR was defined as undetectable ctDNA within 3 to 9 weeks of treatment initiation. Results: Pre-treatment ctDNA burden, but not blood tumor mutation burden, predicted survival. Implementing a tumor-naïve WBC DNA-informed approach increased the number of evaluable cases without compromising the overall accuracy of landmark ctDNA mR. A direct comparison of single-timepoint on-therapy ctDNA assessment with ctDNA dynamics from baseline to the 3- to 9-week interval, along with an analysis of heterogeneity in mR within the 3- to 9-week window, showed that undetectable ctDNA at the landmark timepoint can effectively predict survival outcomes. A significant enrichment in landmark ctDNA mR was noted among patients with progression-free survival (PFS) ≥6 months on immunotherapy (P = 2.5e−05) or chemoimmunotherapy (P = 0.02). Patients in the landmark mR group had longer PFS (P = 1.6e−06) and overall survival (P = 2.5e−05) than those with molecular progression. Conclusions: Landmark ctDNA mR provides a real-time, accurate approach for monitoring immunotherapy clinical outcomes. Although not currently validated for regulatory use, these findings demonstrate the potential validity of ctDNA as an early endpoint of immunotherapy response.
- 24 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF19
Open AccessLandmark ctDNA Molecular Response Represents an Early Predictor of Immunotherapy Outcomes in Lung Cancer: A Clinical Validity Study
Purpose: Circulating tumor DNA (ctDNA) analyses are informative as an early indicator of immunotherapy response in advanced non–small cell lung cancer (NSCLC); however, the clinical value of ctDNA molecular response (mR) requires further validation. Experimental Design: As part of a prospective clinical protocol (NCT05995821), we conducted targeted error-correction sequencing of ctDNA (n = 328) and matched white blood cell (WBC) DNA (n = 109) from 109 patients with metastatic NSCLC who received anti–PD-(L)1 either as monotherapy or in combination. Following cellular origin resolution of 2,818 variants, landmark mR was defined as undetectable ctDNA within 3 to 9 weeks of treatment initiation. Results: Pre-treatment ctDNA burden, but not blood tumor mutation burden, predicted survival. Implementing a tumor-naïve WBC DNA-informed approach increased the number of evaluable cases without compromising the overall accuracy of landmark ctDNA mR. A direct comparison of single-timepoint on-therapy ctDNA assessment with ctDNA dynamics from baseline to the 3- to 9-week interval, along with an analysis of heterogeneity in mR within the 3- to 9-week window, showed that undetectable ctDNA at the landmark timepoint can effectively predict survival outcomes. A significant enrichment in landmark ctDNA mR was noted among patients with progression-free survival (PFS) ≥6 months on immunotherapy (P = 2.5e−05) or chemoimmunotherapy (P = 0.02). Patients in the landmark mR group had longer PFS (P = 1.6e−06) and overall survival (P = 2.5e−05) than those with molecular progression. Conclusions: Landmark ctDNA mR provides a real-time, accurate approach for monitoring immunotherapy clinical outcomes. Although not currently validated for regulatory use, these findings demonstrate the potential validity of ctDNA as an early endpoint of immunotherapy response.
- 13 September 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (22) , 5034-5041
Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group
Early indicators of metastatic cancer response to therapy are important for evaluating new drugs and stopping ineffective treatment. The RECIST guidelines based on repeat cancer imaging are widely adopted in clinical trials, are used to identify active regimens that may change practice, and contribute to regulatory approvals. However, these criteria do not provide insight before 6 to 12 weeks of treatment and typically require that patients have measurable disease. Recent data suggest that measuring on-treatment changes in the amount or proportion of ctDNA in peripheral blood plasma may accurately identify responding and nonresponding cancers at earlier time points. Over the past year, the RECIST working group has evaluated current evidence for plasma ctDNA kinetics as a treatment response biomarker in metastatic cancers and early endpoint in clinical trials to identify areas of focus for future research and validation. Here, we outline the requirement for large standardized trial datasets, greater scrutiny of optimal ctDNA collection time points and assay thresholds, and consideration of regulatory body guidelines and patient opinions. In particular, clinically meaningful changes in plasma ctDNA abundance are likely to differ by cancer type and therapy class and must be assessed before ctDNA can be considered a potential pan-cancer response evaluation biomarker. Despite the need for additional data, minimally invasive on-treatment ctDNA measurements hold promise to build upon existing response assessments such as RECIST and offer opportunities for developing novel early endpoints for modern clinical trials.
- 13 September 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (22) , 5034-5041
Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group
Early indicators of metastatic cancer response to therapy are important for evaluating new drugs and stopping ineffective treatment. The RECIST guidelines based on repeat cancer imaging are widely adopted in clinical trials, are used to identify active regimens that may change practice, and contribute to regulatory approvals. However, these criteria do not provide insight before 6 to 12 weeks of treatment and typically require that patients have measurable disease. Recent data suggest that measuring on-treatment changes in the amount or proportion of ctDNA in peripheral blood plasma may accurately identify responding and nonresponding cancers at earlier time points. Over the past year, the RECIST working group has evaluated current evidence for plasma ctDNA kinetics as a treatment response biomarker in metastatic cancers and early endpoint in clinical trials to identify areas of focus for future research and validation. Here, we outline the requirement for large standardized trial datasets, greater scrutiny of optimal ctDNA collection time points and assay thresholds, and consideration of regulatory body guidelines and patient opinions. In particular, clinically meaningful changes in plasma ctDNA abundance are likely to differ by cancer type and therapy class and must be assessed before ctDNA can be considered a potential pan-cancer response evaluation biomarker. Despite the need for additional data, minimally invasive on-treatment ctDNA measurements hold promise to build upon existing response assessments such as RECIST and offer opportunities for developing novel early endpoints for modern clinical trials.
- 1 November 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 5 (5) , 1443-1448
Ovarian Failure Preceding Head and Neck Squamous Cell Carcinoma Identifies an Adult-Onset Cancer-Prone Syndrome Caused by FANCM Mutations
- 1 November 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 5 (5) , 1443-1448
Ovarian Failure Preceding Head and Neck Squamous Cell Carcinoma Identifies an Adult-Onset Cancer-Prone Syndrome Caused by FANCM Mutations
- 21 October 2021
- Published by Elsevier in Leukemia Research
- Vol. 111, 106731
Re-induction therapy in adult patients with acute myeloid leukemia with ≤20 % blasts: A retrospective cohort study
- 21 October 2021
- Published by Elsevier in Leukemia Research
- Vol. 111, 106731
Re-induction therapy in adult patients with acute myeloid leukemia with ≤20 % blasts: A retrospective cohort study